Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoko Inaguma

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Blood|September 3, 2010
BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemiaYukiya Yamamoto, Sachiko Tsuzuki, Motohiro Tsuzuki, et al.
Histopathology|February 24, 2017
Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cellsAkiko Ohashi, Seiichi Kato, Akinao Okamoto, et al.
Pathology International|November 20, 2018
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorderTeerada Daroontum, Kei Kohno, Yoko Inaguma, et al.
Cytogenetic and Genome Research|June 17, 2020
Truncated RUNX1 Generated by the Fusion of RUNX1 to Antisense GRIK2 via a Cryptic Chromosome Translocation Enhances Sensitivity to Granulocyte Colony-Stimulating FactorAkihiro Abe, Yukiya Yamamoto, Akira Katsumi, et al.
International Journal of Hematology|March 31, 2015
The fate of patients with acute myeloid leukemia not undergoing induction chemotherapyMasamitsu Yanada, Akinao Okamoto, Yoko Inaguma, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2016
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphomaAyana Tomono, Kaori Ito, Takahiro Hayashi, et al.
Chemico-Biological Interactions|February 27, 2016
In vitro antiproliferative activity of 2,3-dihydroxy-9,10-anthraquinone induced apoptosis against COLO320 cells through cytochrome c release caspase mediated pathway with PI3K/AKT and COX-2 inhibitionC Balachandran, N Emi, Y Arun, et al.
International Journal of Hematology|January 20, 2016
TP53 mutations in older adults with acute myeloid leukemiaMasamitsu Yanada, Yukiya Yamamoto, Sachiko Iba, et al.
Hematology (Amsterdam, Netherlands)|January 17, 2013
Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: a single-center experienceAkinao Okamoto, Masamitsu Yanada, Yoko Inaguma, et al.
Oncology|September 30, 2016
Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell LymphomaKaori Ito, Masataka Okamoto, Yoko Inaguma, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Blood|September 3, 2010
BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemiaYukiya Yamamoto, Sachiko Tsuzuki, Motohiro Tsuzuki, et al.
Histopathology|February 24, 2017
Reappraisal of Epstein-Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cellsAkiko Ohashi, Seiichi Kato, Akinao Okamoto, et al.
Pathology International|November 20, 2018
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma arising in patient with a history of EBV-positive mucocutaneous ulcer and EBV-positive nodal polymorphous B-lymphoproliferative disorderTeerada Daroontum, Kei Kohno, Yoko Inaguma, et al.
Cytogenetic and Genome Research|June 17, 2020
Truncated RUNX1 Generated by the Fusion of RUNX1 to Antisense GRIK2 via a Cryptic Chromosome Translocation Enhances Sensitivity to Granulocyte Colony-Stimulating FactorAkihiro Abe, Yukiya Yamamoto, Akira Katsumi, et al.
International Journal of Hematology|March 31, 2015
The fate of patients with acute myeloid leukemia not undergoing induction chemotherapyMasamitsu Yanada, Akinao Okamoto, Yoko Inaguma, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2016
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin lymphomaAyana Tomono, Kaori Ito, Takahiro Hayashi, et al.
Chemico-Biological Interactions|February 27, 2016
In vitro antiproliferative activity of 2,3-dihydroxy-9,10-anthraquinone induced apoptosis against COLO320 cells through cytochrome c release caspase mediated pathway with PI3K/AKT and COX-2 inhibitionC Balachandran, N Emi, Y Arun, et al.
International Journal of Hematology|January 20, 2016
TP53 mutations in older adults with acute myeloid leukemiaMasamitsu Yanada, Yukiya Yamamoto, Sachiko Iba, et al.
Hematology (Amsterdam, Netherlands)|January 17, 2013
Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: a single-center experienceAkinao Okamoto, Masamitsu Yanada, Yoko Inaguma, et al.
Oncology|September 30, 2016
Influence of R-CHOP Therapy on Immune System Restoration in Patients with B-Cell LymphomaKaori Ito, Masataka Okamoto, Yoko Inaguma, et al.
Pageof 3